Law360, New York (January 26, 2012, 8:10 PM ET) -- Pharmaceutical giants AstraZeneca AB, Merck Sharp & Dohme Corp. and KBI Inc. reached a settlement Thursday with Indian drugmaker Lupin Ltd. in a patent dispute over stomach acid reflux drug Nexium.
U.S. District Judge Joel A. Pisano signed off on the settlement agreement — whose terms were not publicly disclosed — dismissing all claims in the dispute without prejudice and without costs or attorneys’ fees to any of the parties in the dispute.
Sweden-based AstraZeneca and New Jersey-based KBI had sued Lupin in October 2009, claiming...
AstraZeneca, Lupin Soothe Nexium Patent Fight
To view the full article, take a free trial now.
